Review of NICE Technology Appraisal Guidance No.311; Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Proposal to move the existing guidance to the static list
The planned date for review of the above guidance is February 2017.
This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.
No new evidence has been identified that is likely to lead to a change in the existing recommendations.
Consequently we propose that TA311 should move to the ‘static list’ of technology appraisals.
Please see appendix A for a full list of the organisations we have contacted.
This page was last updated: